DE69912375T2 - Adenosin a1 rezeptor antagonisten enthaltende zusammensetzung und verfahren zur wiederherstellung der diuretischen- und nierenfunktion - Google Patents
Adenosin a1 rezeptor antagonisten enthaltende zusammensetzung und verfahren zur wiederherstellung der diuretischen- und nierenfunktion Download PDFInfo
- Publication number
- DE69912375T2 DE69912375T2 DE69912375T DE69912375T DE69912375T2 DE 69912375 T2 DE69912375 T2 DE 69912375T2 DE 69912375 T DE69912375 T DE 69912375T DE 69912375 T DE69912375 T DE 69912375T DE 69912375 T2 DE69912375 T2 DE 69912375T2
- Authority
- DE
- Germany
- Prior art keywords
- diuretic
- adenosine
- furosemide
- pharmaceutical composition
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002934 diuretic Substances 0.000 title claims abstract description 85
- 230000001882 diuretic effect Effects 0.000 title claims abstract description 68
- 239000002598 adenosine A1 receptor antagonist Substances 0.000 title claims abstract description 36
- 230000003907 kidney function Effects 0.000 title claims abstract description 22
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title abstract description 18
- 229940124258 Adenosine A1 receptor antagonist Drugs 0.000 title description 6
- 229960003883 furosemide Drugs 0.000 claims description 77
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 77
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 64
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 27
- 229960005305 adenosine Drugs 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- 238000001914 filtration Methods 0.000 claims description 22
- 208000004880 Polyuria Diseases 0.000 claims description 20
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 claims description 15
- 229960001288 triamterene Drugs 0.000 claims description 15
- 239000002171 loop diuretic Substances 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 150000002148 esters Chemical class 0.000 claims description 12
- 229960002256 spironolactone Drugs 0.000 claims description 12
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- UJEWTUDSLQGTOA-UHFFFAOYSA-N Piretanide Chemical compound C=1C=CC=CC=1OC=1C(S(=O)(=O)N)=CC(C(O)=O)=CC=1N1CCCC1 UJEWTUDSLQGTOA-UHFFFAOYSA-N 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 11
- 229960004064 bumetanide Drugs 0.000 claims description 11
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 claims description 11
- 229960001085 piretanide Drugs 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000035619 diuresis Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000012544 monitoring process Methods 0.000 claims description 5
- 239000005557 antagonist Substances 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 208000018583 New-onset refractory status epilepticus Diseases 0.000 claims 1
- OQCJPFYWFGUHIN-GJKBLCTNSA-N O=C1N(CCC)C(=O)N(CCC)C2=C1NC([C@@H]1[C@@H]3C[C@@H]([C@H]4O[C@H]43)C1)=N2 Chemical compound O=C1N(CCC)C(=O)N(CCC)C2=C1NC([C@@H]1[C@@H]3C[C@@H]([C@H]4O[C@H]43)C1)=N2 OQCJPFYWFGUHIN-GJKBLCTNSA-N 0.000 description 71
- 239000011734 sodium Substances 0.000 description 48
- 210000002700 urine Anatomy 0.000 description 46
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 44
- 229910052708 sodium Inorganic materials 0.000 description 44
- 241000700159 Rattus Species 0.000 description 39
- 230000000694 effects Effects 0.000 description 39
- 230000029142 excretion Effects 0.000 description 33
- 230000001965 increasing effect Effects 0.000 description 27
- 229940030606 diuretics Drugs 0.000 description 22
- 206010007559 Cardiac failure congestive Diseases 0.000 description 17
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 17
- 239000011591 potassium Substances 0.000 description 17
- 229910052700 potassium Inorganic materials 0.000 description 17
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- 230000004044 response Effects 0.000 description 16
- 229960002003 hydrochlorothiazide Drugs 0.000 description 15
- 230000001452 natriuretic effect Effects 0.000 description 15
- 230000007423 decrease Effects 0.000 description 14
- 230000009103 reabsorption Effects 0.000 description 14
- 238000001802 infusion Methods 0.000 description 12
- 230000037396 body weight Effects 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 10
- 206010019280 Heart failures Diseases 0.000 description 9
- 210000005239 tubule Anatomy 0.000 description 9
- 206010003445 Ascites Diseases 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 210000000512 proximal kidney tubule Anatomy 0.000 description 8
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000003792 electrolyte Substances 0.000 description 7
- 230000012495 positive regulation of renal sodium excretion Effects 0.000 description 7
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000012530 fluid Substances 0.000 description 6
- 238000013222 sprague-dawley male rat Methods 0.000 description 6
- 108010060263 Adenosine A1 Receptor Proteins 0.000 description 5
- 102000030814 Adenosine A1 receptor Human genes 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 238000011067 equilibration Methods 0.000 description 5
- 238000005048 flame photometry Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000000885 nephron Anatomy 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000004043 responsiveness Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000003451 thiazide diuretic agent Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 4
- 206010016807 Fluid retention Diseases 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 230000007882 cirrhosis Effects 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000000004 hemodynamic effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229960000278 theophylline Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 101150007969 ADORA1 gene Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010047139 Vasoconstriction Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 210000002565 arteriole Anatomy 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000000210 loop of henle Anatomy 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 230000025033 vasoconstriction Effects 0.000 description 3
- 102000009346 Adenosine receptors Human genes 0.000 description 2
- 108050000203 Adenosine receptors Proteins 0.000 description 2
- 0 CCCN(c1c(C(N2*)=O)nc(C3C(C4)C5OC5C4C3)[n]1)C2=O Chemical compound CCCN(c1c(C(N2*)=O)nc(C3C(C4)C5OC5C4C3)[n]1)C2=O 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010062237 Renal impairment Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010041277 Sodium retention Diseases 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940121359 adenosine receptor antagonist Drugs 0.000 description 2
- 229960002576 amiloride Drugs 0.000 description 2
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000011863 diuretic therapy Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002497 edematous effect Effects 0.000 description 2
- 230000008713 feedback mechanism Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005977 kidney dysfunction Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000025627 positive regulation of urine volume Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- HGAZMNJKRQFZKS-UHFFFAOYSA-N chloroethene;ethenyl acetate Chemical compound ClC=C.CC(=O)OC=C HGAZMNJKRQFZKS-UHFFFAOYSA-N 0.000 description 1
- 229960002155 chlorothiazide Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000006864 diuretic response Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000002637 fluid replacement therapy Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000019948 ion homeostasis Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 229940097271 other diuretics in atc Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000021023 sodium intake Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000035433 tubuloglomerular feedback Effects 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8302298P | 1998-04-24 | 1998-04-24 | |
| US83022P | 1998-04-24 | ||
| US8363898P | 1998-04-30 | 1998-04-30 | |
| US83638P | 1998-04-30 | ||
| PCT/US1999/008879 WO1999055339A1 (en) | 1998-04-24 | 1999-04-23 | Adenosine a1 receptor antagonist containing composition and method for restoring diuretic and renal function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69912375D1 DE69912375D1 (de) | 2003-12-04 |
| DE69912375T2 true DE69912375T2 (de) | 2004-08-19 |
Family
ID=26768857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69912375T Expired - Lifetime DE69912375T2 (de) | 1998-04-24 | 1999-04-23 | Adenosin a1 rezeptor antagonisten enthaltende zusammensetzung und verfahren zur wiederherstellung der diuretischen- und nierenfunktion |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0994711B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2002506463A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE252905T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU3757999A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2295101C (cg-RX-API-DMAC7.html) |
| DE (1) | DE69912375T2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2211079T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1999055339A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0970696A1 (en) * | 1998-05-05 | 2000-01-12 | Kyowa Hakko Kogyo Co., Ltd. | Combination of loop diuretics with adenosine A1-receptor antagonists |
| NZ527917A (en) | 1999-11-12 | 2005-03-24 | Biogen Inc | Polycycoalkylpurines as adenosine receptor antagonists |
| CN1859913A (zh) * | 2003-04-25 | 2006-11-08 | 美国诺华卡迪亚公司 | 改善肾功能损伤个体多尿症的方法 |
| EP1932529A1 (en) * | 2003-04-25 | 2008-06-18 | Novacardia, Inc. | Method of improved diuresis in individuals with impaired renal function |
| US20050239759A1 (en) * | 2004-04-16 | 2005-10-27 | Lauren Otsuki | Method of treatment of disease using an adenosine A1 receptor antagonist and an aldosterone inhibitor |
| WO2018153898A1 (de) * | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit mineralocorticoid-rezeptor-antagonisten |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB998971A (en) * | 1961-09-21 | 1965-07-21 | Societé Civile Nova | Improvements in or relating to medicines having a diuretic action |
| DE3305935C2 (de) * | 1983-02-21 | 1985-05-30 | Medice Chem.-Pharm. Fabrik Pütter GmbH & Co KG, 5860 Iserlohn | Kaliumneutrales Saluretikum mit antihypertensiver Wirkung |
| JPS61271226A (ja) * | 1985-05-24 | 1986-12-01 | Chemo Sero Therapeut Res Inst | 利尿剤 |
| JPH01254664A (ja) * | 1988-04-04 | 1989-10-11 | Daiichi Rajio Isotope Kenkyusho:Kk | 新規ピリジニウム−テクネチウム９９ｍ錯体 |
| JP2689023B2 (ja) * | 1990-08-17 | 1997-12-10 | バクスター、インターナショナル、インコーポレイテッド | ヘモグロビンオリゴマーに基づく組成物及びその製造方法 |
| DE4238367A1 (de) * | 1992-11-13 | 1994-05-19 | Boehringer Ingelheim Kg | Diuretisches Mittel |
| US5446046A (en) * | 1993-10-28 | 1995-08-29 | University Of Florida Research Foundation | A1 adenosine receptor agonists and antagonists as diuretics |
| US5726156A (en) * | 1995-03-06 | 1998-03-10 | Trega Biosciences, Inc. | Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels |
-
1999
- 1999-04-23 WO PCT/US1999/008879 patent/WO1999055339A1/en not_active Ceased
- 1999-04-23 JP JP55433199A patent/JP2002506463A/ja not_active Ceased
- 1999-04-23 CA CA002295101A patent/CA2295101C/en not_active Expired - Fee Related
- 1999-04-23 AT AT99919985T patent/ATE252905T1/de not_active IP Right Cessation
- 1999-04-23 ES ES99919985T patent/ES2211079T3/es not_active Expired - Lifetime
- 1999-04-23 AU AU37579/99A patent/AU3757999A/en not_active Abandoned
- 1999-04-23 DE DE69912375T patent/DE69912375T2/de not_active Expired - Lifetime
- 1999-04-23 EP EP99919985A patent/EP0994711B1/en not_active Expired - Lifetime
-
2009
- 2009-01-26 JP JP2009014811A patent/JP2009102399A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0994711A1 (en) | 2000-04-26 |
| CA2295101A1 (en) | 1999-11-04 |
| AU3757999A (en) | 1999-11-16 |
| ES2211079T3 (es) | 2004-07-01 |
| JP2009102399A (ja) | 2009-05-14 |
| ATE252905T1 (de) | 2003-11-15 |
| DE69912375D1 (de) | 2003-12-04 |
| JP2002506463A (ja) | 2002-02-26 |
| WO1999055339A1 (en) | 1999-11-04 |
| WO1999055339A8 (en) | 1999-12-29 |
| EP0994711B1 (en) | 2003-10-29 |
| CA2295101C (en) | 2009-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69003229T2 (de) | Entzündungshemmendes Mittel in einer Zusammensetzung. | |
| DE2823174A1 (de) | Arzneimittel fuer die prophylaktische behandlung postoperativer tiefer venenthrombose | |
| DE69605531T2 (de) | Carnitinderivat als Arzneimittel zur Behandlung von Arteriosklerose obliterans | |
| DE19734293A1 (de) | Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen | |
| DE3119460A1 (de) | Pharmazeutische zusammensetzung aus l-karnitin und/oder l-acylkarnitin und verwendung der zusammensetzung gegen diabetes mellitus bei jugendlichen | |
| US6818647B2 (en) | Method and composition for restoring diuretic and renal function | |
| DE3643119A1 (de) | Therapeutische zusammensetzung fuer diabetes-komplikationen | |
| JP2009102399A (ja) | 利尿機能および腎機能を回復するためのアデノシンａ１レセプターアンタゴニスト含有組成物および方法 | |
| DE2854316C2 (cg-RX-API-DMAC7.html) | ||
| DE69812028T2 (de) | Creatine Derivate für Asthma | |
| US20050038017A1 (en) | Method and composition for restoring diuretic and renal function | |
| EP1397128B1 (de) | Kappa-opiatagonist für die behandlung der reizblase | |
| DE69008466T2 (de) | Verwendung des 6-[[3-[4-(2-Methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-Dimethyluracils zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Harnwegsverstopfungen. | |
| DE3874900T2 (de) | Wirkstoff mit die nierenfunktion verbesserndem und diuretischem effekt und verwendung eines darin enthaltenen benzothiazepin-derivates. | |
| DE3213579C2 (cg-RX-API-DMAC7.html) | ||
| DE602004012593T2 (de) | Kombinationen aus valsartan, amilorid oder triamterin und einem diuretikum | |
| EP0673913B1 (de) | Calcium-Alkalicitratverbindungen und deren Verwendung als Arzneimittel | |
| EP0032564A1 (de) | Pharmazeutische Verwendung von Caroverin und/oder Caroverinsalzen sowie Caroverinsalze mit Xanthinderivat-Säureresten und Nicotinsäurerest | |
| DE2615694A1 (de) | Pharmazeutische zusammensetzungen | |
| EP1919483B1 (de) | Kombinationspräparat aus einem thiaziddiuretikum und einem schleifendiuretikum | |
| DE69430864T2 (de) | Verfahren und zusammensetzungen zur behandlung der osteoporose | |
| DE69427927T2 (de) | Verwendung von Trimetazidin zur Herstellung von Medikamenten für die Behandlung von Gesundheitsstörungen, die durch die Nephrotoxizität von Cyclosporin A bedingt sind. | |
| DE3874978T2 (de) | Ponalrestat enthaltendes hyperurikaemie-mittel. | |
| DE3887005T2 (de) | Mittel zur Behandlung von Nierenbeschwerden. | |
| DE3317280C2 (cg-RX-API-DMAC7.html) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: CV THERAPEUTICS, PALO ALTO, CALIF., US |
|
| 8364 | No opposition during term of opposition |